Section 53
Chapter 52,200

Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy

Azakami, T.; Hayes, C.N.; Sezaki, H.; Kobayashi, M.; Akuta, N.; Suzuki, F.; Kumada, H.; Abe, H.; Miki, D.; Tsuge, M.; Imamura, M.; Kawakami, Y.; Takahashi, S.; Ochi, H.; Nakamura, Y.; Kamatani, N.; Chayama, K.

Journal of Medical Virology 83(6): 1048-1057


ISSN/ISBN: 1096-9071
PMID: 21503919
DOI: 10.1002/jmv.22069
Accession: 052199383

Download citation:  

An association between a single nucleotide polymorphism (SNP) in the inosine triphosphate pyrophosphatase (ITPA) gene and reduction of hemoglobin during peg-interferon plus ribavirin combination therapy for patients with chronic hepatitis C virus (HCV) infection has been reported. However, the effect of the SNP on outcome of therapy has not been fully elucidated. Factors associated with anemia during combination therapy, including rs1127354 genotype, were analyzed in 1,002 treated patients. The effect of the SNP on outcome of therapy was analyzed in a subset of 830 patients with genotype 1. A rapid initial decrease in hemoglobin levels was observed in patients with rs1127354 genotype CC compared with a slow decrease in non-CC patients. Cumulative reduction of ribavirin was significantly more frequent in genotype CC patients than non-CC patients (odds ratio 1.928, P = 8.6 × 10(-8) ). The frequency of patients who received at least the recommended 80% of scheduled ribavirin was significantly lower among genotype CC patients, especially among those who had pretreatment hemoglobin levels between 13.5 and 15 g/dl (P < 0.03), and the sustained viral response rate was significantly lower in this group of patients. Independent predictive factors for sustained virological response included a SNP in the IL28B locus (rs809991), age, fibrosis, ITPA SNP rs1127354 as well as pretreatment hemoglobin levels. Our data suggests that measures to prevent anemia should be considered for patients who have pretreatment hemoglobin levels less than 13.5 g/dl or who have rs1127354 genotype CC and pretreatment hemoglobin levels between 13.5 and 15 g/dl.

PDF emailed within 0-6 h: $19.90